Prior to these studies, we knew, for example, that BRAF and NRAS mutations occurred but tumour sequencing studies have helped us to resolve their absolute prevalence, particularly at positions outside of the canonical BRAFV600 and NRASQ61 residues. The gene discussed is BRAF; the disease is neoplasm.